Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1386 - New candidate biomarkers discerning benign liver tumors from hepatocellular carcinoma (42P)


18 Nov 2017


Poster lunch


Translational Research;  Hepatobiliary Cancers


Anton Budko


Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653


A. Budko1, M. Chesnokov1, P. Skovorodnikova2, D. Shavochkina1, I. Kustova1, N. Kudashkin3, Y. Patyutko3, N. Lazarevich1

Author affiliations

  • 1 Laboratory Of Epithelial Tumors Progression Mechanisms, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2 Biological Faculty,, Lomonosov Moscow State University, 119992 - Moscow/RU
  • 3 Institute Of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU


Abstract 1386


Hepatocellular carcinoma (HCC) is the most common form of malignant liver tumors, characterized by unfavorable prognosis and low sensitivity to chemotherapy. HCC diagnosis is complicated by late manifestation of symptoms and lack of effective biomarkers. The existing MRI approach does not cover 20% of HCC cases (hypovascular variants). Another problem is differential diagnosis between G1-stage HCC and subclasses of hepatocellular adenoma (HCA). Present study examines the ability of potential biomarkers, previously identified by our group, to differentiate HCC from benign liver tumors represented by HCA and focal nodular hyperplasia (FNH). We also analyzed gene expression changes associated with the development of FNH and HCA in order to identify molecular markers capable of distinguishing between these two neoplasm types.


61 pairs of surgical biopsies of tumor and non-tumorous liver tissue of patients with HCA (5 cases), FNH (6 cases) and HCC (50 cases) were used in the study. Expression levels of RAB3B, IQGAP3, GPC3, HKDC1, TOP2A, GNAZ, PDGFA and CENPF genes were evaluated using RT-qPCR. Data on gene expression changes were statistically processed and sorted using hierarchical cluster analysis.


Significant (p 


Overexpression of IQGAP3, GPC3, CENPF and TOP2A genes is specific for HCC, but not HCA and FNH, so these genes are promising candidate biomarkers for differential diagnosis of benign and malignant liver tumors. Activation of RAB3B and HKDC1 genes in FNH and HCA tissue suggests their possible role in the development of these neoplasms. Specific patterns of gene expression changes described for HCA and FNH indicate the difference in molecular mechanisms underlying their pathogenesis and provide a tool for distinguishing these neoplasms from each other.

Clinical trial identification

Legal entity responsible for the study

Prof. Natalia L. Lazarevich, PhD, DSc Head of Laboratory of Epithelial Tumors Progression Mechanisms, Institute of Carcinogenesis, N.N. Blokhin Russian Cancer Research Center of Russian Ministry of Health, Moscow, Russian Federation.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.